| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918017 | Radiotherapy and Oncology | 2014 | 5 Pages |
Abstract
Different planning protocols resulted in different levels of PTV dose homogeneity. We observed differences of up to ⩾7 Gy in composite and individual mean OAR doses. This could influence rates of toxicity and should be taken into account when comparing clinical studies. A consensus should be reached between major trial groups on appropriate PTV parameters.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jim P. Tol, Max Dahele, Patricia Doornaert, Ben J. Slotman, Wilko F.A.R. Verbakel,